Back to Search
Start Over
Ingenol mebutate as topical treatment for actinic keratosis based on a prospective, non-interventional, multicentre study of real-life clinical practice in Germany: efficacy and quality of life
- Source :
- European Journal of Dermatology. 29:401-408
- Publication Year :
- 2019
- Publisher :
- John Libbey Eurotext, 2019.
-
Abstract
- The use of ingenol mebutate (IM) as a field-directed therapy over a short period of time has been shown to be effective and well tolerated in randomized Phase III trials. To assess the efficacy and patient-reported outcomes for IM as treatment for actinic keratosis (AK) under daily “real-life” practice conditions. A total of 826 adult patients with AK were enrolled by 292 dermatologists in Germany in a prospective, open, non-interventional, non-controlled, multicentre study. All patients were treated with IM and followed for eight weeks. The mean number of clinically visible AK lesions decreased significantly from 7.1±6.8 to 2.8±4.5 (p
- Subjects :
- Adult
Ingenol Mebutate Gel
medicine.medical_specialty
Time Factors
Administration, Topical
Ingenol mebutate
Dermatology
Risk Assessment
Severity of Illness Index
Drug Administration Schedule
030207 dermatology & venereal diseases
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Quality of life
Germany
Humans
Medicine
Patient Reported Outcome Measures
Prospective Studies
Adverse effect
Dose-Response Relationship, Drug
business.industry
Actinic keratosis
Middle Aged
medicine.disease
Keratosis, Actinic
Clinical trial
Treatment Outcome
Tolerability
chemistry
030220 oncology & carcinogenesis
Quality of Life
Observational study
Diterpenes
business
Follow-Up Studies
Subjects
Details
- ISSN :
- 19524013 and 11671122
- Volume :
- 29
- Database :
- OpenAIRE
- Journal :
- European Journal of Dermatology
- Accession number :
- edsair.doi.dedup.....0ad45af0b574e69de5e5972394281ea9